Home » Stocks » CERC

Cerecor Inc. (CERC)

Stock Price: $3.66 USD 0.29 (8.61%)
Updated Mar 1, 2021 11:46 AM EST - Market open
Market Cap 298.21M
Revenue (ttm) -3.52M
Net Income (ttm) -46.24M
Shares Out 74.90M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $3.66
Previous Close $3.37
Change ($) 0.29
Change (%) 8.61%
Day's Open 3.54
Day's Range 3.50 - 3.74
Day's Volume 219,802
52-Week Range 1.52 - 4.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

ROCKVILLE, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for r...

GlobeNewsWire - 1 month ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor”; NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and comm...

GlobeNewsWire - 1 month ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercializati...

GlobeNewsWire - 1 month ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercializati...

GlobeNewsWire - 1 month ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercializati...

GlobeNewsWire - 2 months ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercializati...

GlobeNewsWire - 2 months ago

Initial data anticipated in the first quarter of 2021 Initial data anticipated in the first quarter of 2021

GlobeNewsWire - 3 months ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercializati...

GlobeNewsWire - 3 months ago

ROCKVILLE, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments f...

GlobeNewsWire - 3 months ago

On track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year end

GlobeNewsWire - 4 months ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercializati...

GlobeNewsWire - 5 months ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercializ...

GlobeNewsWire - 6 months ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercializ...

GlobeNewsWire - 6 months ago

The data strongly support Cerecor’s ongoing clinical study of CERC-002 as a novel potential treatment for COVID-19-related ARDS The data strongly support Cerecor’s ongoing clinical study of CE...

GlobeNewsWire - 6 months ago

-Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement

GlobeNewsWire - 6 months ago

ROCKVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare ped...

GlobeNewsWire - 6 months ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatment...

GlobeNewsWire - 6 months ago

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatment...

GlobeNewsWire - 7 months ago

Top-line Data Anticipated in Fourth Quarter 2020 Top-line Data Anticipated in Fourth Quarter 2020

GlobeNewsWire - 8 months ago

ROCKVILLE, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for...

GlobeNewsWire - 8 months ago

ROCKVILLE, Md., June 09, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for...

GlobeNewsWire - 8 months ago

ROCKVILLE, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for...

GlobeNewsWire - 10 months ago

-Appoints Sol J. Barer, Ph.D. as Chairman of the Board- Appoints Suzanne Bruhn, Ph.D. and Joseph Miller as Directors to the Board

GlobeNewsWire - 11 months ago

ROCKVILLE, Md., March 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments fo...

GlobeNewsWire - 11 months ago

ROCKVILLE, Md., March 06, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments fo...

GlobeNewsWire - 1 year ago

-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases  -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer

GlobeNewsWire - 1 year ago

-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases -Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medica...

GlobeNewsWire - 1 year ago

ROCKVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for...

GlobeNewsWire - 1 year ago

-Deal Valued in Excess of $32 Million -Eliminates Debt Associated with Avadel / Deerfield Agreement -Provides Non-Dilutive Cash Generation to Fund R&D  -Extends Runway Towards NDA Su...

Market Watch - 1 year ago

Shares of Cerecor Inc. CERC, +2.96% rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S.

GlobeNewsWire - 1 year ago

ROCKVILLE, Md., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for...

About CERC

Cerecor, a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat comp... [Read more...]

Industry
Biotechnology
IPO Date
Oct 15, 2015
CEO
Michael F. Cola
Employees
18
Stock Exchange
NASDAQ
Ticker Symbol
CERC
Full Company Profile

Financial Performance

In 2019, Cerecor's revenue was $6.75 million, a decrease of -3.96% compared to the previous year's $7.03 million. Losses were -$16.07 million, -59.87% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Cerecor stock is "Buy." The 12-month stock price forecast is 14.00, which is an increase of 282.51% from the latest price.

Price Target
$14.00
(282.51% upside)
Analyst Consensus: Buy